Published in

Elsevier, Urology Case Reports, 2(3), p. 21-23, 2015

DOI: 10.1016/j.eucr.2015.01.002

Links

Tools

Export citation

Search in Google Scholar

Prostate Cancer and Li-Fraumeni Syndrome: Implications for Screening and Therapy

Journal article published in 2015 by Colleen K. Spees ORCID, Kelly J. Kelleher, Ronney Abaza, Steven K. Clinton
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Li-Fraumeni Syndrome (LFS) is an autosomal dominant genetic disorder associated with mutations in the TP53 gene and characterized by a propensity to develop a variety of malignancies resulting in a shortened lifespan. We report a case of prostate cancer in a 50 year old male with LFS. Experimental studies suggest that TP53 mutations in prostate cancer are associated with therapeutic resistance to radiation, chemotherapy, and anti-androgens, implying that LFS men may experience more aggressive cancer biology with implications for therapeutic decisions. The potential of prostate cancer to develop earlier in LFS favors institution of screening at earlier ages.